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Summary
Background Weekly adalimumab (Humira) is approved for the treatment of
hidradenitis suppurativa (HS) based on the 12-week placebo-controlled periods
of the two phase III PIONEER trials.
Objectives Using PIONEER integrated trial results, we aimed to evaluate the optimal
medium-term adalimumab maintenance dosing strategy for moderate-to-severe
HS.
Methods Each trial had two double-blind periods; 12-week Period A and 24-week
Period B. Patients randomized to adalimumab 40 mg every week (ADAew) (Per-
iod A), were rerandomized in Period B to ADAew (ADAew/ew), ADA every
other week (ADAew/eow), or placebo (ADAew/pbo). Placebo-randomized
patients were reassigned in Period B to ADAew (PIONEER I) or placebo (PIO-
NEER II). The primary outcome was HS Clinical Response (HiSCR). Patients who
lost response during Period B were discontinued from the study and offered an
option to enter the open-label extension (OLE) to receive ADAew. Results are
reported across the two study periods, and data were combined from the two
study periods and the OLE.
Results For week-12 HiSCR achievers, the HiSCR week-36 rate was 481%
(ADAew/ew) vs. 462% (ADAew/eow) and 321% (ADAew/pbo). Combining
(post hoc) these patients with week-12 partial responders further differentiated
outcomes in Period B (ADAew/ew 557% vs. ADAew/eow 400% and ADAew/
pbo 301%). Period-B adverse-event rates were ADAew/ew 596% vs. ADAew/
eow 574% and ADAew/pbo 650%. One patient (ADAew/ew) reported a seri-
ous infection.
Conclusions Weekly adalimumab treatment, effective throughout 36 weeks, was
the optimal maintenance medium-term dosing regimen for this population. At
least partial response after 12 weeks with continued weekly dosing had better
outcomes than dose reduction or interruption. Patients who do not show at least
a partial response to weekly adalimumab by week 12 are unlikely to benefit from
continued therapy. No new safety risks were identified.
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What’s already known about this topic?
• Hidradenitis suppurativa (HS) is a chronic inflammatory disease, commonly misin-
terpreted as an infection and treated with long-term antibiotic regimens or surgical
incisions.
• Based on the chronicity of HS and the lack of evidence for efficacious and safe
long-term HS treatments, it is important to evaluate medium- to long-term thera-
pies for HS.
• Weekly adalimumab (Humira) is approved for the treatment of moderate-to-
severe HS based on the two phase III PIONEER trials.
What does this study add?
• This study pooled data from the two PIONEER trials, providing a more robust
assessment of outcomes.
• After at least partial treatment success with weekly adalimumab short-term therapy
(12 weeks), continuing weekly dosing during the subsequent 24 weeks had better
outcomes than dose reduction or treatment interruption.
• Patients who do not show at least a partial response to weekly adalimumab by
week 12 are unlikely to benefit from continued therapy.
Hidradenitis suppurativa (HS) or acne inversa is a serious,
painful, systemic chronic skin disease, which may persist
for decades.1–3 Inflammatory skin lesions including
abscesses, fistulas and nodules, may exhibit purulent,
malodorous drainage, and develop tunnels (sinus tracts)4
and scarring as disease severity increases.2,5 Lesions may
flare, resolve and recur in different body areas. As a result,
patients with moderate-to-severe HS carry a substantial dis-
ease burden.6,7
HS is not an infection. Evidence suggests that it is an
inflammatory disease with a pathogenesis that is multifacto-
rial.8 However, antibiotic treatment has historically played a
central role in managing this disease.9 In view of the
chronicity of the disease and the lack of evidence for efficacy
and safety of any type of HS therapy beyond short-term
therapy,9 it is important to evaluate medium- to long-term
therapies.10–15
The tumour necrosis factor (TNF)-a antibody, adali-
mumab (Humira, AbbVie Inc., North Chicago, IL,
U.S.A.), is currently the only approved pharmacological
therapy for the treatment of adults with moderate-to-severe
HS. In initial trials, 40 mg adalimumab every-week treat-
ment was efficacious in controlling objective signs of mod-
erate-to-severe disease and in reducing pain during the
first 12–16 weeks.16,17 The objective of this analysis was
to evaluate the optimal medium-term adalimumab mainte-
nance dosing strategy from integrated results of the PIO-
NEER I and II trials, and from the initial 36-week portion
of the open-label extension (OLE) trial that paralleled the
PIONEER trials. The safety and efficacy of adalimumab
weekly dosing with dosage reduction and with
maintenance of treatment response off therapy were also
explored.
Patients and methods
Study design and participants
PIONEER I and II had similar study designs. Each was 36
weeks in duration with two double-blind periods, i.e. 12-
week Period A and 24-week Period B (Fig. 1). Patients who
lost response or had worsening or absence of improvement in
Period B (defined in Fig. 1) were allowed to enter the OLE.
Adults were enrolled if they were anti-TNF-a naive, had
moderate-to-severe disease [total abscess and inflammatory
nodule (AN) count of at least three at baseline, and HS lesions
in two distinct body areas, one of which was classified as
Hurley stage II or III],18 and had an inadequate response to
oral antibiotics used to treat HS. Baseline antibiotics (tetracy-
cline class) in stable doses were allowed in PIONEER II. Com-
plete eligibility criteria and ethical standards have been
published elsewhere.17
At enrolment, patients were randomized to receive adali-
mumab 40 mg weekly dosing (ADAew) or matching placebo.
Patients treated with adalimumab continuing to Period B were
rerandomized at week 12 to ADAew, adalimumab every-
other-week dosing (ADAeow), or matching placebo (pbo)
(1 : 1 : 1 ratio); patients who received placebo were reas-
signed to ADAew in PIONEER I or remained on placebo in
PIONEER II. All patients were assigned in a blinded fashion.
Randomization and blinding details have been previously pub-
lished elsewhere.17
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Assessments
This is an integrated (pooled) analysis from Period B of the
two PIONEER trials and the initial portion of the OLE that par-
alleled the 36 weeks of the PIONEER trials. The statistical anal-
ysis plan prespecified the primary end point as achievement of
HS Clinical Response (HiSCR) at week 36; assessed by nonre-
sponder imputation (missing or early transfer to OLE were
imputed as nonresponders). HiSCR was defined as at least a
50% reduction from baseline in total AN count, with no
increase in abscess or draining-fistula counts; this represents
clinically meaningful lesion changes and has been previously
described.17,19,20
Statistical analysis
The primary population for the integrated analysis of efficacy
was the intention-to-treat population (ITT). In Period A, this
included all patients randomized at week 0, and in Period B,
all patients who received ADAew in Period A and were reran-
domized to Period B (Fig. 2). Randomization in Period B was
stratified based on patients’ HiSCR status at the end of Period
A (week 12) and baseline Hurley stage. Treatment groups in
Period B were categorized according to the dose received in
Periods A and B (ADAew/ew, ADAew/eow, ADAew/pbo).
Period-B efficacy analysis subpopulations (Fig. 2) included
(i) patients who achieved HiSCR at week 12 (week-12 HiSCR
responders); (ii) patients who did not achieve HiSCR at week
12 (week-12 HiSCR nonresponders); and (iii) patients who
received continuous ADAew dosing during both periods (all-
ADAew population). HiSCR up to week 36 was also evaluated
for patients who transferred early to the OLE.
An additional population was defined post hoc to identify
the most clinically appropriate patient group for continued
treatment of ADAew (continued from Period A to Period B)
over the medium term vs. adalimumab discontinuation
(ADAew/pbo) (Fig. 2 and File S1; see Supporting Informa-
tion).21,22 The resulting population combined the week-12
Randomizaon 1:1d
Screening
Period A
Double-blind Placebo-controlled
12 weeks
Period Ba
Double-blind Placebo-controlled
24 weeks
0 12 16Week:
Open-Label Extension (OLE)b
Adalimumab 40 mg weekly
At least 60 weeks
Adalimumab 40 mg weeklyc
Placebo (PIONEER II)
(PIONEER I)
At compleon of 
Period B: opon to 
enter OLE
HiSCR Responders at Period-B entry, with LOR 
in Period B: opon to enter OLE aer week 12
HiSCR Non-Responders at Period-B entry,
with WOAI in Period B: opon to enter 
OLE starng at week 16
Adalimumab 40 mg every-other-week
Placebo
Adalimumab 40 mg weeklyf
Placebo
36
Adalimumab 40 mg weeklye
Fig 1. Study design.
aWeek-12 Hidradenitis Suppurativa (HS) Clinical Response (HiSCR) responders through Period B to week 36 or until loss of response [loss of
50% of the abscess and inflammatory nodule (AN) count improvement gained between baseline and week 12], and week-12 HiSCR
nonresponders continued Period B to at least week 26 (and up to week 36). bPatients could enter the multicentre 60-week phase III OLE trial
(which evaluated long-term safety, tolerability and efficacy of adalimumab for patients with moderate-to-severe HS), if (i) they completed Period
B of their respective PIONEER trial; (ii) achieved HiSCR at entry to Period B of their respective PIONEER trial and then experienced a loss of
response (LOR); or (iii) did not achieve HiSCR at the entry of Period B and then experienced worsening or absence of improvement (WOAI)
(greater or equal to the baseline AN count on two consecutive visits after week 12, occurring at least 14 days apart). cStarting at week 4 after 160
mg (week 0), 80 mg (week 2). dStratified by baseline Hurley stage II vs. Hurley stage III (PIONEER I and II) and baseline concomitant antibiotic
use (PIONEER II). eRerandomization for patients treated with adalimumab in Period A was stratified by week-12 HiSCR status at entry into Period
B and by baseline Hurley stage II vs. Hurley stage III. fAdalimumab 40 mg starting at week 16 after 160 mg (week 12), 80 mg (week 14).
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HiSCR responders with patients who did not achieve HiSCR at
week 12, but did achieve a partial response at week 12, i.e. ≥
25% reduction in AN count relative to baseline (week-12 par-
tial responders) to form the week-12 partial responders plus
HiSCR responders (PRR) population (Fig. 2).
The integrated efficacy for Period B adjusted for study,
baseline Hurley stage, and week-12 HiSCR status. Analysis of
covariance was used for continuous variables, and the
Cochran–Mantel–Haenszel test analysed discrete variables. The
efficacy analysis in Period B conducted pairwise comparisons
of each adalimumab arm vs. placebo in the Period-B ITT pop-
ulation. According to the study design, patients who lost
response during Period B were required to discontinue the
study and enter the OLE to receive ADAew, and were counted
as nonresponders in the subsequent Period-B visit, even if the
patients regained response while continuing ADAew treatment
in the OLE. To adjust for this potential study-design artifact,
medium-term efficacy of ADAew treatment was also summa-
rized in the all-ADAew population to include data from both
the initial PIONEER studies and the OLE study.
Safety was analysed for all patients in the Period-A ADAew
group who received at least one dose of study drug in Period B.
Results
Of the 633 patients from PIONEER I and II who were ran-
domized in Period A, 300 of the 316 patients assigned to
ADAew entered Period B and were included in the Period B
efficacy analyses; 300 patients were treated and included in
the Period B safety analysis (Fig. S1; see Supporting
Information). The primary reason for study discontinuation in
Period B was meeting the protocol-specified criteria for loss of
response or worsening or absence of improvement (defined in
Fig. 1). These patients were allowed to transfer early to the
OLE. More in the ADAew/pbo group transferred early com-
pared with the other groups (50 ADAew/pbo, 40 ADAew/
eow, 35 ADAew/ew). Compliance (ratio of number of
received vs. planned injections of study drug, verified by
patient diaries) with study drug administration was high; the
overall mean rate in Period B was 986% for ADAew/pbo,
983% for ADAew/eow and 975% for ADAew/ew.
Baseline demographics, disease characteristics, and
comorbidity were generally balanced across the Period-B
treatment groups and were typical for a study population
with moderate-to-severe HS (Table 1). The majority of
these patients were female (623%), white (827%) and
obese [mean body mass index = 322 kg m2 (n = 299)].
Median duration of HS was 89 years (range 1–435), and
the mean number of ANs at baseline markedly exceeded the
minimum number required for study entry (at least three).
Mean high-sensitivity C-reactive protein was elevated [170
mg L1 (SD 239)].
Efficacy
For all patients rerandomized after ADAew treatment in Period
A (Period-B ITT population), the proportion achieving HiSCR
at week 36 in the ADAew/ew group was higher (434%)
compared with the ADAew/eow group (307%) and signifi-
cantly higher (P < 005) compared with the ADAew/pbo
Period-B ITT Populaon
Paents re-randomized in Period B aer receiving ADAew in Period A  
(N=300)
ADAew/ew (All-ADAew Populaon): 99 
ADAew/eow: 101 
ADAew/pbo: 100 
Week-12 HiSCR Responders
(N=157)
ADAew/ew: 52 
ADAew/eow: 52
ADAew/pbo: 53
Week-12 Paral Responders (post hoc)
(Non-HiSCR responder with >25% reducon 
in AN count at week 12)
(N=56)
ADAew/ew: 18 
ADAew/eow: 18 
ADAew/pbo: 20 
Week-12 Non-Responders (post hoc) 
(<25% reducon in AN count )
(N=87)
ADAew/ew: 29 
ADAew/eow: 31
ADAew/pbo: 27
Week-12 Paral Responders + HiSCR Responders (PRR) (post hoc)
(N=213)
ADAew/ew: 70 
ADAew/eow: 70 
ADAew/pbo: 73 
Fig 2. Efficacy analysis population and subpopulations. ITT, intention to treat; ADA, adalimumab; ew, weekly dosing; pbo, placebo; eow, every-
other-week dosing; HiSCR, Hidradenitis Suppurativa Clinical Response; AN, total abscess and inflammatory nodule count.
© 2019 The Authors British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2019)
4 Adalimumab medium-term dosing strategy for hidradenitis suppurativa, G.B.E. Jemec et al.
group (280%) (Fig. 3a). Patients remaining on continuous
weekly treatment, did experience fluctuation in disease activ-
ity, as shown by a median AN-count increase of one (in-
terquartile range 0–4) from week 12, at the time point with
highest activity during Period B. In comparison, those who
withdrew from weekly dosing in Period B had a median AN-
count increase of three (interquartile range 1–6).
The HiSCR rate reduced over time during Period B for all
treatment groups (Fig. 2a). For the week-12 HiSCR responders,
all treatment groups also had a reduction in the HiSCR rate over
time during Period B. Respective HiSCR rates at week 14 and
week 36 were 792% and 321% for ADAew/pbo; 788% and
462% for ADAew/eow; 731% and 481% for ADAew/ew.
The HiSCR rate at week 36 in the ADAew/ew group was higher
(481%, n/N = 25/52) compared with the ADAew/eow
(462%, n/N = 24/52) and ADAew/pbo groups (321%, n/N =
17/53).
Our statistical modelling (File S1; see Supporting Informa-
tion) identified the week-12 PRR population as the group of
patients who would benefit most from continuous weekly
adalimumab treatment. For this population, the HiSCR rate for
the ADAew/ew group at week 36 was higher (557%, n/N =
39/70) compared with the ADAew/eow group (400%, n/N
= 28/70) and significantly higher (P < 001) compared with
the ADAew/pbo group (301%, n/N = 22/73) (Fig. 3b).
HiSCR rates declined slightly for all groups during Period B.
For the few week-12 HiSCR nonresponders (< 25% reduc-
tion in AN count), the HiSCR rates at week 36 were 138%
(n/N = 4/29) for ADAew/ew, 97% (n/N = 3/31) for
ADAew/eow and 222% (n/N = 6/27) for ADAew/pbo.
Patients in the all-ADAew population (N = 99) who
received continuous ADAew dosing during Periods A and B,
including records from the OLE period for those who discon-
tinued Period B early and continued ADAew in the OLE,
Table 1 Patient characteristics and comorbidities at baseline
Period B (all patients receiving ADAew in Period A), N = 300
ADAew/pbo, N = 100 ADAew/eow, N = 101 ADAew/ew, N = 99 Total, N = 300
Male, n (%) 44 (44) 36 (356) 33 (333) 113 (377)
Female, n (%) 56 (56) 65 (644) 66 (667) 187 (623)
Ethnicity, n (%)
White 81 (81) 77 (762) 90 (909) 248 (827)
Black 13 (13) 19 (188) 6 (61) 38 (127)
Othera 6 (6) 5 (49) 3 (58) 12 (40)
Age, years, median (range) 35 (20–67) 36 (19–63) 34 (18–64) 35 (18–67)
BMI, kg m2, median (range) 326 (174–535);
(N = 99)
305 (183–534) 315 (203–545) 316 (174–545);
(N = 299)
BMI,b kg m2; n (%)
Normal weight (< 25) 21 (212) 21 (208) 14 (141) 56 (187)
Overweight (25 to < 30) 19 (192) 26 (257) 26 (263) 71 (237)
Obese (30 to < 40) 44 (444) 39 (386) 48 (485) 131 (438)
Morbidly obese (≥ 40) 15 (152) 15 (149) 11 (111) 41 (137)
Current nicotine use, n (%) 54 (540) 65 (644) 59 (596) 178 (593)
Disease characteristics
Hurley stage II, n (%) 55 (55) 52 (515) 49 (495) 156 (520)
Hurley stage III, n (%) 45 (45) 49 (485) 50 (505) 144 (480)
Modified Sartorius score,
median (range)
107 (18–397) 100 (19–433) 104 (20–1093) 1595 (18–1093)
Family history of HS, n (%) 23 (23) 21 (210) 29 (293) 73 (244)
Median disease duration,
years (range)
82 (11–435) 85 (11–333) 101 (10–404) 89 (10–435)
HS lesions; mean (SD)
AN 131 (997) 121 (1052) 121 (1014) 125 (1019)
Abscess 28 (359) 26 (306) 20 (261) 24 (312)
Draining fistula 41 (490) 38 (511) 36 (423) 38 (475)
Inflammatory nodule 103 (796) 97 (974) 101 (944) 100 (905)
Daily pain at worst,
median (range 0–10)
47 (0–10); (N = 97) 50 (0–10); (N = 100) 44 (0–97); (N = 97) 47 (0–10); (N = 294)
Prior surgery for HS, n (%) 16 (16) 17 (168) 11 (111) 44 (147)
hsCRP, mg L1 mean (SD) 164 (1912); (N = 52) 177 (2280) 169 (2482) 170 (2231); (N = 299)
pbo, placebo; ADAew, adalimumab every-week dosing; BMI, body mass index; HS, hidradenitis suppurativa; AN, abscesses and inflammatory
nodules; hsCRP, high-sensitivity C-reactive protein. a‘Other’ includes Asian [n = 4 (4%) ADAew/pbo; n = 3 (30%) ADAew/eow; and n = 7
(23%) all ADAew] and other ethnicities than those mentioned in this table and table footnote [n = 1, (10%) ADAew/pbo, n = 2, (20%)
ADAew/eow, n = 2, (20%) ADAew/ew, and n = 5, (17%) all ADAew]. bMissing data for one patient (ADAew/pbo).
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maintained treatment response through week 36 (535%,
535%, 586% and 556% achieved HiSCR at weeks 12, 20,
32 and 36, respectively; Fig. 4).
Safety
Treatment-emergent adverse events included worsening of HS
(Table 2). In Period B, the rate of any adverse event was
lowest for the ADAew/ew group (596%) compared with the
ADAew/eow (574%) and ADA/pbo groups (650%). Overall,
the adverse event profile was similar between the ADAew/ew
and ADAew/eow groups. The most frequently reported seri-
ous adverse event was worsening of HS (Period B: n = 2
ADAew/pbo, n = 3 ADAew/eow). The percentage reporting a
serious infection was highest in the ADAew/ew group (10%)
compared with the ADAew/eow (0%) and placebo groups
28·0
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(a) (b)
Fig 3. Achievement of Hidradenitis Suppurativa Clinical Response (HiSCR) at week 36 for patients who received adalimumab (ADA) every week
(ew) in Period A. (a) Period-B intention-to-treat population. Overall, patients rerandomized to ADAew did better in Period B than those
rerandomized to ADA every other week (eow) or placebo (pbo). The pbo/pbo group was included only in the PIONEER II study; hence, a
comparison between the other treatment groups and the pbo/pbo group was not performed (it is shown here for illustration purposes only). (b)
Week-12 partial responder plus HiSCR responders (PRR). This population was identified as the patients most likely to benefit from weekly
adalimumab treatment continued past week 12. Nonresponder imputation. Statistical significance at ***P = 0001, **P = 001, *P = 005 for
ADAew/ew vs. ADA ew/pbo; +P = 005 for ADAew/ew vs. ADAew/eow; and #P = 005 for ADAew/eow vs. ADAew/pbo. P-values were
calculated using the Cochran–Mantel–Haenszel test adjusted for study, baseline Hurley stage and HiSCR responder at entry of Period B (Fig. 3a),
and HiSCR status at rerandomization (Fig. 3b).
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Fig 4. Maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR) for patients receiving continuous adalimumab (ADA) every week
(ADAew) across PIONEER I, II and open-label extension (OLE). Patients in this analysis are those who received ADAew in both study periods (all-
ADAew population, N = 99). This analysis includes data from both study periods, in addition to the OLE data for the all-ADAew population who
discontinued Period B owing to loss of response, entered the OLE, and regained response in the OLE. This demonstrates maintenance of treatment
response for patients who may regain response following temporary loss of response.
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(0%). One patient (ADAew/ew group) reported a serious
infection and one patient (ADAew/eow group) reported non-
melanoma skin cancer (squamous cell carcinoma of the nasal
slope). A fatal event of cardiorespiratory arrest occurred in a
patient (ADAew/eow group) who had multiple cardiovascular
risk factors. No patients reported opportunistic infection,
tuberculosis (active or latent), lymphoma or demyelinating
disorder.
Discussion
HS is a chronic disease that often begins in young adulthood
and lasts for decades.23 As a result, developing optimally effec-
tive medium- and long-term evidence-based treatment strate-
gies remains an active and acute need for these patients.
Although antibiotics are often effective in the short term, there
is a lack of evidence of medium- to long-term antibiotic treat-
ment for HS.24,25
This pooled analysis from weeks 12 to 36 of PIONEER I
and II is consistent with an optimal medium-term adalimumab
dosing strategy of continuing weekly adalimumab after week
12, as efficacy outcomes generally favoured the weekly dosing
arm, and safety outcomes for those patients were not worse
compared with the other dosing arms. Pooling the observa-
tions was appropriate based on the similarities of the studies,
and provided a more robust assessment by combining the
somewhat limited sample sizes in Period B of each study.
Overall, for patients who received ADAew in Period A,
those who continued on ADAew in Period B had better HiSCR
outcomes compared with those rerandomized to every-other-
week dosing or to treatment discontinuation (placebo).
Weekly treatment also resulted in significantly better HiSCR
outcomes compared with placebo in all subgroups, except
where subgroup sizes were small. In addition, week-12 HiSCR
responders who continued ADAew in Period B, showed better
maintenance of response than those rerandomized to a
reduced dosing regimen or to treatment discontinuation. From
a clinical perspective, individual patients should expect fluctu-
ations in their response to treatment, which clinicians should
take into consideration when administering long-term treat-
ment with weekly adalimumab dosing.
A systematic reduction in HiSCR was observed in all treat-
ment groups during Period B of the PIONEER trials. The
apparent rate reduction over time using only the assessments
from Period B for week-12 HiSCR responders during Period
B, could be due in part to the study design, which forced
patients who lost response during Period B to discontinue the
study and enter the OLE, even if the loss of response may
have resulted from temporary disease exacerbation, which is
common owing to the waxing and waning nature of HS.26,27
This was addressed by integrating data from the PIONEER
studies and from the OLE, which allowed these patients to
demonstrate whether they could achieve HiSCR during contin-
ued treatment with ADAew throughout the OLE. The result
showed maintenance of treatment response from week 12
(535%) to week 36 (556%). This may represent a more
clinically relevant picture of treatment as it accounts for dis-
ease-related fluctuations in treatment response, and illustrates
that a loss of treatment response is not necessarily permanent.
Despite small patient numbers in the week-12 partial
responders (≥ 25% reduction in AN count) population who
continued on ADAew, when this group was combined with
the week-12 HiSCR responders (i.e. PRR), the response at
week 36 with continued weekly dosing was greater than for
the week-12 HiSCR responders alone, and was also greater
than every-other-week dosing or placebo. This suggests that
Table 2 Treatment emergent adverse events in Period B
For patients who received ADAew in Period A, n (%) ADAew/pbo, (N = 100) ADAew/eow, (N = 101) ADAew/ew (N = 99)
Any adverse event 65 (65) 58 (574) 59 (596)
Serious adverse eventsa 2 (2) 5 (50) 3 (30)
Adverse event leading to study drug discontinuation 2 (2) 2 (20) 2 (20)
Infection 29 (29) 31 (307) 32 (323)
Serious infectionb 0 0 1 (10)
Malignancy 0 1 (10) 0
Nonmelanoma skin cancer 0 1 (10) 0
Psoriasis-related adverse eventsc 1 (1) 1 (10) 3 (30)
Adverse events leading to deathd 0 1 (10) 0
Adverse events in ≥ 10% of patients in any group
Nasopharyngitis 10 (10) 4 (40) 6 (61)
Worsening of hidradenitis suppurativa (HS) 20 (20) 18 (178) 5 (51)
ADA, adalimumab; ew, every-week dosing; eow, every-other-week dosing; pbo, placebo. aSerious adverse events included the following:
lymphadenitis, acute myocardial infarction, cardiorespiratory arrest, abortion induced (ADAew/eow, n = 1 for each); pneumonia, ectopic
pregnancy (ADAew/ew, n = 1 for each); HS (ADAew/pbo, n = 2; ADAew/eow, n = 3) and rash (ADAew/ew, n = 1). bSerious infections
included pneumonia (ADAew/ew, n = 1). cEvents of worsening or new onset included dermatitis psoriasiform (ADAew/pbo, n = 1;
ADAew/ew, n = 2); psoriasis (ADAew/eow, n = 1; ADAew/ew, n = 1). dOne death owing to cardiorespiratory arrest occurred 42 days after
the last dose of ADA in a 35-year-old man with a history of diabetes mellitus, smoking and a family history of coronary heart disease. Events
include worsening of underlying HS disease.
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continuous weekly dosing is the most effective strategy over
the subsequent 24 weeks for patients with at least a partial
response to an initial 12 weeks of weekly treatment.
For those not achieving HiSCR by week 12, a partial
response (≥ 25% reduction in AN count) at week 12 appeared
to be predictive of later response, and HiSCR response was
more likely with continued ADAew treatment vs. dose reduc-
tion or dose withdrawal, so allowing these patients enough
time to respond to treatment is an important consideration.
Continuing weekly dosing for patients with partial response is
supported by the outcomes of other end points for this popu-
lation, including reduced rates of flare, pain and lower lesion
counts among patients rerandomized to weekly vs. every-
other-week dosing or placebo.28 One caveat is that the small
number of patients who achieved a partial HiSCR response
precludes the possibility of robust, reliable inferences about
characteristics that could predict an eventual HiSCR response.
Adalimumab weekly treatment provides an effective treat-
ment option for patients with HS, but there is room for
improvement. Although a clinical benefit was shown in the
long term in 43% of patients overall at week 36, it is clear
that further research for treatment options and targets should
be pursued.
There appeared to be little safety risk with continuing
weekly adalimumab therapy for patients with HS who had at
least a partial response (≥ 25% reduction in AN count) by 12
weeks of weekly treatment, as the number and nature of
adverse events for patients who received medium-term (up to
36 weeks) weekly treatment (all-ADAew population) did not
show an increasing incidence. Additional benefits from weekly
dosing during the first 12 weeks of the trials compared with
placebo, included significant pain reduction and significantly
better treatment response across subgroups. Regardless of
whether patients were at Hurley stage II or III and whether
antibiotic therapy was used,17 the baseline burden of disease
was very similar, as were efficacy results.
For patients with a < 25% reduction in AN count at week
12, continuing weekly adalimumab treatment beyond week
12 yielded outcomes similar to placebo, suggesting that con-
tinuation of adalimumab treatment for patients without at
least a partial response at week 12 cannot be recommended.
This analysis was limited by the small number of patients
in the week-12 HiSCR partial responder population who were
rerandomized to weekly adalimumab dosing, and in the
week-12 HiSCR nonresponder population, and by the post
hoc nature of the analyses for the PRR group.
After an induction dose, continuous adalimumab 40 mg
weekly dosing was an effective medium-term treatment for
patients with moderate-to-severe HS throughout the two PIO-
NEER trials. When achieving at least partial treatment success
with adalimumab short-term therapy, patients who continued
on weekly dosing had better outcomes than those who were
switched to every-other-week dosing or those whose treatment
was interrupted. Patients with a < 25% reduction in AN count
after 12 weeks of initial adalimumab weekly treatment did not
demonstrate benefit from further adalimumab treatment.
Conversely, it is important to note that the response trajectory
for patients achieving > 25% but < 50% reduction in AN count
in the first 12 weeks, may be delayed and, therefore, longer
treatment periods may be needed to optimize disease improve-
ment in this group. No new safety risks were identified with
adalimumab weekly dosing through 36 weeks of treatment.
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